2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.106 Brandi Oakley Abstract

PP01.106 Brandi Oakley Abstract

Pdf Summary

A study has validated the Immunotherapy Response Score (IRS) as a predictive biomarker for determining the benefit of pembrolizumab monotherapy in non-small cell lung cancer (NSCLC) patients. Pembrolizumab is approved for first-line treatment of NSCLC patients with PD-L1 expression, creating a need for biomarkers to guide treatment decisions. The IRS has previously been validated to predict the benefit of pembrolizumab and other anti-PD-1/PD-L1 antibodies across different tumor types. In this study, the clinical utility of the IRS was assessed in an independent cohort of NSCLC patients with PD-L1 expression.<br /><br />The study included NSCLC patients treated with first-line pembrolizumab monotherapy and had PD-L1 expression measured by immunohistochemistry (IHC). The primary objective was to determine if IRS status added to PD-L1 expression for predicting time to next therapy (TTNT) with pembrolizumab. The analysis included adjusting for age and sex.<br /><br />The results showed that IRS status significantly improved the prediction of pembrolizumab TTNT when added to PD-L1 expression. In the full model, IRS status was significantly associated with pembrolizumab TTNT, while PD-L1 expression was not. Similar results were obtained when using categorical PD-L1 expression instead of continuous values. Kaplan Meier analysis showed that patients with high IRS status had significantly longer TTNT compared to those with low IRS status. However, there was no significant difference in TTNT based on different levels of PD-L1 expression.<br /><br />Overall, this study suggests that the IRS can be a useful biomarker for predicting the benefit of pembrolizumab monotherapy in NSCLC patients with PD-L1 expression. The IRS outperformed PD-L1 expression in predicting treatment response and may be helpful in guiding individualized treatment decisions. Further research is needed to validate these findings and explore the potential of the IRS in other tumor types.

Keywords

Immunotherapy Response Score

IRS

predictive biomarker

pembrolizumab monotherapy

non-small cell lung cancer

NSCLC

PD-L1 expression

biomarkers

treatment decisions

time to next therapy